CARB-X LAUNCHES NEW FUNDING ROUND TO FILL MAJOR R&D GAPS IN GLOBAL PIPELINE
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today a funding solicitation with four distinct product themes:
- THERAPEUTICS FOR INFECTIONS CAUSED BY GRAM-NEGATIVE PATHOGENS
- PREVENTION FOR INVASIVE DISEASE
- DIAGNOSTICS FOR NEONATAL SEPSIS
- PROOF-OF-CONCEPT FOR NOVEL SAMPLE TYPES FOR DIAGNOSING LOWER-RESPIRATORY-TRACT INFECTIONS
Target product profiles and minimal acceptable criteria for all funding calls will be defined and available on carb-x.org.
Expressions of interest for all themes may be submitted during these timeframes:
- 18 March 2024 at 10:00 ET – 29 March 2024 at 23:59 ET
- 23 September 2024 at 10:00 ET – 4 October 2024 at 23:59 ET
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!